A Study of Low-dose Lenalidomide After Non-myeloablative Allogeneic Stem Cell Transplant With Bortezomib as GVHD Prophylaxis in High Risk Multiple Myeloma

Trial Profile

A Study of Low-dose Lenalidomide After Non-myeloablative Allogeneic Stem Cell Transplant With Bortezomib as GVHD Prophylaxis in High Risk Multiple Myeloma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Bortezomib; Ciclosporin; Fludarabine; Mycophenolate mofetil
  • Indications Graft-versus-host disease; Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Feb 2017 Status changed from recruiting to discontinued.
    • 29 Sep 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Apr 2017.
    • 09 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top